Matinas BioPharma (MTNB) AI Stock Analysis

• Market Cap: $4.12M
• Dividend Yield: N/A
• Average Volume (3M): 52.28K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.97
• Revenue Growth: N/A
• EPS Growth: 25.19%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.03
• Shares Outstanding: 6,406,191
• 10 Day Avg. Volume: 45,057
• 30 Day Avg. Volume: 52,280
• PEG Ratio: 0.02
• Price to Book (P/B): 0.33
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.16
• Enterprise Value/Market Cap: 0.12
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -0.20
• Enterprise Value/Ebitda: -0.05
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $0.58 ▼(-10.92% Downside)

The score is primarily weighed down by weak financial performance (no revenue, ongoing losses, and continued cash burn implying financing risk). Technicals are also negative with the stock trading below key moving averages, despite oversold readings that may help near-term stabilization. Valuation provides limited support because the company is loss-making and has no dividend yield data.

Positive Factors

Innovative Technology

Matinas BioPharma's LNC delivery technology enhances drug bioavailability and efficacy, providing a competitive edge in drug delivery solutions.

Strategic Board Appointments

New board members with biotech experience can enhance strategic direction and potentially improve shareholder value, strengthening leadership.

Revenue Model

The revenue model based on licensing and partnerships provides diverse income streams, which can stabilize revenue over time as partnerships mature.

Negative Factors

Declining Revenues

Persistent revenue decline indicates challenges in market penetration and product adoption, affecting long-term financial sustainability.

Negative Cash Flow

Negative cash flow from operations suggests inefficiencies and potential liquidity issues, limiting the company's ability to fund growth initiatives.

Leadership Changes

Frequent leadership changes can disrupt strategic continuity and create uncertainty, potentially impacting long-term strategic execution.

Matinas BioPharma Business Overview & Revenue Model

Company Description

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

How the Company Makes Money

Matinas BioPharma generates revenue through the development and commercialization of its proprietary lipid nano-crystal (LNC) delivery technology. The company engages in research collaborations and license agreements to advance its drug delivery platform, which can enhance the therapeutic effectiveness of existing pharmaceuticals. Revenue is primarily derived from licensing fees, milestone payments, and potential royalties from partnerships with other biotech and pharmaceutical companies. Additionally, Matinas may receive funding from grants or government programs aimed at advancing medical research and innovation. The company's earnings are influenced by the success of its clinical trials, the establishment of strategic partnerships, and the progression of its product pipeline towards commercialization.

Matinas BioPharma Financial Statement Overview

Summary

Matinas BioPharma faces significant financial challenges, with declining revenues and persistent losses affecting its profitability and overall financial health. The balance sheet indicates declining equity and asset values, while cash flow metrics highlight difficulties in generating cash from operations. Strategic changes may be necessary to improve financial performance and stability.

Income Statement

The company has experienced a declining trend in total revenue over the years, with revenue dropping to zero in 2024. The gross profit margin remains negative, indicating cost challenges, and the net profit margin is also negative, reflecting the company's continuous losses. EBIT and EBITDA margins are in the negative territory, showcasing persistent operational challenges. The revenue growth rate is also negative, suggesting declining business activity.

Balance Sheet

The company has a moderate debt-to-equity ratio, indicating manageable leverage. However, the consistent decrease in stockholders' equity and total assets raises concerns about the company's financial stability. The equity ratio is relatively stable but declining, signaling potential risks in maintaining financial health.

Cash Flow

Operating cash flow remains negative, reflecting challenges in generating cash from operations. The free cash flow is also negative, indicating an inability to cover capital expenditures and operational needs. The operating cash flow to net income ratio is unfavorable, suggesting inefficiencies in converting income into cash. However, the company has managed some positive cash inflows from financing activities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	1.10M	3.19M	33.00K	158.33K
Gross Profit	-2.46M	0.00	1.10M	-13.49M	-14.55M	-14.20M
EBITDA	-9.74M	-19.19M	-22.82M	-24.23M	-24.45M	-23.92M
Net Income	-17.48M	-24.25M	-22.94M	-21.00M	-23.28M	-22.45M
Balance Sheet
Total Assets	9.70M	12.64M	25.10M	78.87M	61.33M	70.97M
Cash, Cash Equivalents and Short-Term Investments	5.43M	7.28M	13.76M	28.81M	49.62M	58.68M
Total Debt	2.33M	2.89M	3.56M	4.12M	4.70M	3.75M
Total Liabilities	3.23M	5.05M	5.86M	42.23M	8.83M	7.24M
Stockholders Equity	6.46M	7.59M	19.25M	36.64M	52.49M	63.73M
Cash Flow
Free Cash Flow	-9.01M	-15.88M	-15.50M	-20.05M	-15.48M	-17.37M
Operating Cash Flow	-9.01M	-15.88M	-15.28M	-19.16M	-15.22M	-17.37M
Investing Cash Flow	820.00K	9.21M	13.24M	4.88M	16.77M	-40.67M
Financing Cash Flow	3.33M	9.17M	-7.00K	79.00K	6.96M	48.05M

Matinas BioPharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTNB, the sentiment is Negative. The current price of 0.65 is below the 20-day moving average (MA) of 0.68, below the 50-day MA of 0.87, and below the 200-day MA of 1.09, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 42.43 is Neutral, neither overbought nor oversold. The STOCH value of 62.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MTNB.

Matinas BioPharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NCNA	46 Neutral	$14.03M	-0.02	-179.40%	―	―	94.52%
MTNB	43 Neutral	$4.12M	-0.19	-157.24%	―	―	25.19%
APRE	43 Neutral	$6.61M	-0.43	-74.72%	―	-62.75%	23.87%
HCWB	42 Neutral	$3.30M	-0.09	―	―	-87.93%	65.26%
ADIL	41 Neutral	$6.72M	-0.25	-155.01%	―	―	78.52%

Matinas BioPharma Corporate Events

Matinas BioPharma Amends CEO Employment Agreement

On December 12, 2025, Matinas BioPharma Holdings, Inc. amended its employment agreement with CEO Jerome D. Jabbour, extending the deadline for a Change in Control to June 30, 2026, and modifying the payment structure for his retention bonus. The amendment also includes changes to the definitions of ‘Change in Control,’ ‘Cause,’ and ‘Good Reason,’ impacting the terms under which Mr. Jabbour can receive his bonus, reflecting strategic adjustments in the company’s executive compensation plan.

Matinas BioPharma CFO Resignation Announced

On November 18, 2025, Matinas BioPharma Holdings, Inc. announced that its Chief Financial Officer, Keith Kucinski, has decided to resign, effective January 17, 2026, to pursue other opportunities. The company clarified that his resignation was not due to any disagreements with the company’s operations, policies, or practices.